Fistula Calprotectin as a Biomarker of Local Inflammation and Treatment Response in Perianal Fistulizing Crohn's Disease
Alimentary Pharmacology & Therapeutics · 2026-06 · 63 (11) · 1517-1528
DOI: 10.1111/apt.70600 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Alimentary Pharmacology & Therapeutics, online erschienen am 03.03.2026. Verfasst von Runqi Wang und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China. Hauptthemen laut MEDLINE: Crohn Disease, Leukocyte L1 Antigen Complex, Rectal Fistula, Infliximab. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Shanghai Baoshan District Key Specialties, Shanghai Baoshan District Health Commission Talents Program.
Abstract (Originalsprache)
Background
Accurate assessment of tract‐specific inflammatory activity remains difficult in perianal fistulizing Crohn's disease (pfCD), as current clinical and imaging indices incompletely reflect local activity.
Aims
To evaluate fistula calprotectin (FiCP) as a tract‐specific biomarker, focusing on diagnostic accuracy, associations with histological, clinical, and radiological indices, longitudinal responsiveness, and local infliximab exposure.
Methods
In this single‐center observational study (April 2023–July 2025; n = 105), patients with pfCD provided fistula exudate samples during surgical or outpatient assessment. FiCP concentrations were quantified by ELISA and correlated with histological inflammation, the Perianal Disease Activity Index (PDAI), the MRI‐based modified Van Assche Index (mVAI), and total fistula volume (TFV). Diagnostic performance was analysed using receiver operating characteristic (ROC) curves with DeLong comparison, and treatment responsiveness was evaluated longitudinally using the standardised response mean (SRM). Serum and local infliximab concentrations were measured using ELISA.
Results
FiCP levels were significantly higher in fistulas with severe versus mild histological inflammation ( p = 0.021) and in clinically or radiologically active tracts (both p < 0.001). FiCP correlated with PDAI ( R = 0.61), mVAI ( R = 0.40), and local infliximab concentration ( R = −0.64). FiCP discriminated active from quiescent fistulas (AUC 0.843; 95% CI 0.758–0.928) and retained diagnostic value in patients with normal CDAI scores. FiCP levels declined significantly after therapy and showed greater responsiveness than PDAI and TFV.
Conclusions
FiCP represents a minimally invasive, tract‐specific biomarker that mirrors local inflammatory activity and dynamically tracks treatment response in pfCD. Multicenter validation is warranted to define its clinical utility.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastrointestinal Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
- Department of General Surgery, Baoshan Branch, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
- Department of Clinical Laboratory, Baoshan Branch, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
- Department of Radiology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
- Department of Dermatology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
- Laboratory of Medicine, Baoshan Branch, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
ORCID-Profile: Zhe Cui
Förderung
- National Natural Science Foundation of China
- Shanghai Baoshan District Key Specialties
- Shanghai Baoshan District Health Commission Talents Program
- Shanghai Baoshan District Science and Technology Foundation
- Ren Ji Hospital Baoshan Branch Cultivated Funding for Clinical Research Innovation
Zitieren
APA
Wang, R., Wu, Y., Xu, D., Yang, Y., Qian, K., Kuang, J., Wang, X., Lin, C., Liu, X., Wu, G., Ruan, D., Chen, B., Zhang, Y., Li, Y., Wang, Z., Cui, Z., & Cao, D. (2026). Fistula Calprotectin as a Biomarker of Local Inflammation and Treatment Response in Perianal Fistulizing Crohn's Disease. Alimentary Pharmacology & Therapeutics, 63(11), 1517-1528. https://doi.org/10.1111/apt.70600
Vancouver
Wang R, Wu Y, Xu D, Yang Y, Qian K, Kuang J, et al. Fistula Calprotectin as a Biomarker of Local Inflammation and Treatment Response in Perianal Fistulizing Crohn's Disease. Alimentary Pharmacology & Therapeutics. 2026;63(11):1517-1528. doi:10.1111/apt.70600
BibTeX
@article{Wang2026,
author = {Wang, Runqi and Wu, Yanglong and Xu, Dongbo and Yang, Yeyi and Qian, Keyu and Kuang, Jia and Wang, Xiaohui and Lin, Chaoyi and Liu, Xin and Wu, Guangyu and Ruan, Dandan and Chen, Binghua and Zhang, Ye and Li, Yousheng and Wang, Zheng and Cui, Zhe and Cao, Dongxing},
title = {Fistula Calprotectin as a Biomarker of Local Inflammation and Treatment Response in Perianal Fistulizing Crohn's Disease},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2026},
volume = {63},
number = {11},
pages = {1517--1528},
doi = {10.1111/apt.70600}
}
EUVIMED